Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04149743 · ClinicalTrials.gov registry record · NA
HEMOTAG® Assessment for Short-term Outcomes of Heart Failure
A NA study of Heart Failure (HF), sponsored by Aventusoft.
- Recruiting
- Registry status
- NA
- Development phase
- 420
- Enrollment target
- 2
- Study locations
NCT04149743 is a NA study of Heart Failure (HF) that is actively recruiting participants, run by Aventusoft. The registered enrollment target is 420 participants, above the 38-participant average among 3 other Heart Failure (HF) trials with a reported enrollment target (1005% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT04149743, a NA study of Heart Failure (HF), is actively recruiting participants, sponsored by Aventusoft.
- RECRUITING
- Registry status
- NA
- Development phase
- 420 participants
- Enrollment target
- 2
- Study locations
Study Summary
Evaluation of the HEMOTAG® system in a less controlled environment and concurrently develop the system for use by patients with heart failure.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Standard of Care with Hemotag
Study Locations (2)
Florida
- Cleveland Clinic Florida - Weston
Texas
- Baylor Scott & White Research Institute - Temple
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2022-01-31 |
| Est. Completion | 2024-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04149743
The ClinicalTrials.gov registry entry for NCT04149743 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 38-participant average among 3 other Heart Failure (HF) trials with a reported enrollment target (1005% higher). The listed sponsor is Aventusoft, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure (HF) appearing as the primary indexed condition, and to 1 intervention - of which Standard of Care with Hemotag is the first listed.
NCT04149743 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT04149743 about?
NCT04149743 is a clinical study titled "HEMOTAG® Assessment for Short-term Outcomes of Heart Failure". Evaluation of the HEMOTAG® system in a less controlled environment and concurrently develop the system for use by patients with heart failure.
What is the current status of trial NCT04149743?
This trial is currently recruiting. It is a NA study. The enrollment target is 420 participants. The study started on 2022-01-31. Estimated completion is 2024-12.
What conditions does trial NCT04149743 study?
This clinical trial studies the following conditions: Heart Failure (HF).
What interventions are being tested in trial NCT04149743?
The interventions under investigation include: Standard of Care with Hemotag (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04149743?
This trial is sponsored by Aventusoft, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04149743 being conducted?
This trial has 2 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure (HF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
REsynchronization Comparison In LBBB and Normal or Mildly Reduced VENTricular Function With CRT (REINVENT-CRT)
ACTIVE NOT RECRUITING · NA
-
Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.
COMPLETED · Phase 4
-
A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.